2024-07-10T13:29:35-05:00 2023-12-31 812950760 SAX LLP 1040 AVENUE OF THE AMERICAS-16TH FL NEW YORK NY 10018 990 2023-01-01 133174839 THE GLAUCOMA FOUNDATION INC GLAU 2126511900 80 MAIDEN LANE 700 NEW YORK NY 10038 ELENA STURMAN PRESIDENT & CEO 2126511900 2024-07-10 1 ELENA STURMAN 999009999 0 MIKE SCHALL P02024184 2126618640 2024-06-18 2 AAL1 IAL1 2023 2023-04-26 12:10:37Z ELENA STURMAN 80 MAIDEN LANE 700 NEW YORK NY 10038 6494685 0 X GLAUCOMAFOUNDATION.ORG X 1984 NY TGF IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA. 24 24 5 60 0 0 2557425 2676417 0 0 325797 2086669 30000 0 2913222 4763086 445000 999750 0 0 938742 932746 30000 30875 292449 770999 914976 2184741 2878347 728481 1884739 12309626 13946604 554217 709973 11755409 13236631 X THE GLAUCOMA FOUNDATION IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA, THE LEADING CAUSE OF PREVENTABLE BLINDNESS. THE STRATEGY TO ACHIEVE THIS GOAL IS TWO-FOLD: RAISE PUBLIC AWARENESS CONCERNING THE NECESSITY OF ROUTINE EYE EXAMS, AND FUND CRITICAL RESEARCH TO FIND CURES FOR GLAUCOMA. 0 0 764168 SEE SCHEDULE OEDUCATION:1) MULTIPLE WEBINARS: WHAT DO COLD HANDS HAVE TO DO WITH GLAUCOMA? THE PROMISE OF OPTIC NERVE REGENERATION;THE BODY-EYE RELATIONSHIP HOW TO SAVE THE SIGHT OF PATIENTS WITH GLAUCOMA WHILE MINIMIZING ADVERSE REACTION FROM EYE DROPS;INSIGHTS INTO GLAUCOMA & WOMEN'S HEALTH: EXPLORING THE IMPACT OF MENOPAUSE AND VISUAL FUNCTION;GLAUCOMA AND LIFESTYLE.2) THE 28TH ANNUAL OPTIC NERVE RESCUE AND RESTORATION THINK TANK "A PATIENT-CENTRIC APPROACH WHILE INCORPORATING THE LATEST SCIENCE" GLAUCOMA DATA INTEGRATION:OVERVIEW OF DATABASES AVAILABLE TO ADVANCE GLAUCOMA KNOWLEDGE;LESSONS LEARNED ABOUT GLAUCOMA FROM THE UK BIOBANK;POAG GENOMIC ARCHITECTURE;A 360-DEGREE BIOMEDICAL PROFILE OF HEALTH: LESSONS FROM CARDIOVASCULAR DISEASE.3) DRUG RE-PURPOSING IN GLAUCOMA:INSULIN SIGNALING AND;METFORMIN AND GLAUCOMA;GLP-1R AGONISTS AND GLAUCOMA;4) OVERVIEW OF GLAUCOMA NEUROPROTECTION AGENTS:WHY DO WE NOT HAVE A NEUROPROTECTION AGENT FOR GLAUCOMA?HOW CAN AI HELP FACILITATE RANDOMIZED CLINICAL TRIALS IN NEUROPROTECTION?5) SEX HORMONES AND GLAUCOMA:THE ROLE OF SEX HORMONES IN THE PATHOGENESIS OF OPEN-ANGLE GLAUCOMA: EVIDENCE FROM EPIDEMIOLOGICAL STUDIES;ESTROGEN SIGNALING PATHWAYS IN GLAUCOMA;THE BIOMECHANICAL ARGUMENT THAT ESTROGEN PLAYS A ROLE IN GLAUCOMA;6) NON-IOP FACTORS OF IMPORTANCE IN GLAUCOMA:DIET AND GLAUCOMA;HYPERTENSION, ANTIHYPERTENSIVE DRUGS AND GLAUCOMA;THE IMPACT OF GLAUCOMA ON ACTIVITIES OF DAILY LIVING.7) WHAT CAN TGF DO TO HELP PATIENTS, RESEARCHERS, AND EYECARE PROVIDERS TACKLE GLAUCOMA? :WHAT IS THE GLAUCOMA FOUNDATION DOING NOW?WHAT DO PATIENTS WANT TO SEE IN GLAUCOMA RESEARCH?8) START WITH THE YOUNGINFO SESSION ON GLAUCOMA FOR MIDDLE AND HIGH SCHOOL STUDENTS;IN COORDINATION WITH THE STEM INSTITUTE AT THE CITY COLLEGE OF NEW YORK.9) NEWSLETTERS: TGF PRODUCED SIX ELECTRONIC NEWSLETTERS THAT WERE DISTRIBUTED TO MORE THAN 16,000 HOUSEHOLDS. TGF'S QUARTERLY PRINTED NEWSLETTERS WERE AVAILABLE FOR CONSTITUENTS WHO DO NOT USE COMPUTERS OR WHO PREFER TO READ PAPER DOCUMENTS. NEWSLETTERS INCLUDE INTERVIEWS WITH DOCTORS, RESEARCHERS, AND PATIENTS. THEY COVER TOPICS SUCH AS ADVANCEMENTS IN DIAGNOSIS AND TREATMENT, PERSPECTIVES ON CARE, AND PERSONAL STORIES OF LIVING WITH THE DISEASE. 1525496 999750 SEE SCHEDULE OMEDICAL RESEARCH:1) GENETIC PREDISPOSITION AND OPHTHALMIC OUTCOMES;2) OPTIC NERVE REGENERATION;3) USING ARTIFICIAL INTELLIGENCE TO REVEAL BLOOD PRESSURE'S ROLE IN GLAUCOMA PROGRESSION;4) EE-PURPOSING AN "OLD" DRUG FOR A NEW INDICATION: ELUCIDATING THE PERIPHERAL AND CENTRAL EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS TO TREAT GLAUCOMA; 5) SEARCH FOR FUNCTIONAL LOXL1 RISK ALLELES WITH BIT-STARR;6) VASCULAR GENOTYPE-PHENOTYPE ASSOCIATION IN PRIMARY OPEN-ANGLE GLAUCOMA;7) INVESTIGATING THE ROLE OF IMPAIRED MITOCHONDRIAL DYNAMICS IN EXFOLIATION GLAUCOMA;8) UNCOVERING THE POTENTIAL OF PERICYTES AS THERAPEUTIC TARGETS FOR GLAUCOMA;9) NICOTINAMIDE AND PYRUVATE FOR NEUROENHANCEMENT IN OPEN-ANGLE GLAUCOMA: A PHASE 2 RANDOMIZED CLINICAL TRIAL. 2289664 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 5 1 0 0 0 0 0 0 0 0 0 0 0 0 X 24 24 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 NY AL AK AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X ELENA STURMAN 2122850080 80 MAIDEN LANE SUITE 700 NEW YORK NY 10038 GREGORY K HARMON CHAIRMAN 1.00 X X 0 0 0 ROBERT RITCH FOUNDER 1.00 X X 0 0 0 KENNETH MORTENSON CHAIR, INVESTMENT COMMITTEE 1.00 X X 0 0 0 BALDO SCASSELLATI SFORZOLINI DIRECTOR 1.00 X 0 0 0 SALVATORE CIAMPO DIRECTOR 1.00 X 0 0 0 REZA DIBADJ DIRECTOR 1.00 X 0 0 0 MURRAY FINGERET DIRECTOR 1.00 X 0 0 0 DAVID FELLOWS DIRECTOR 1.00 X 0 0 0 BARRY S FRIEDBERG DIRECTOR 1.00 X 0 0 0 JEFFREY M LIEBMANN DIRECTOR 1.00 X 0 0 0 KUMAR MAHADEVA DIRECTOR 1.00 X 0 0 0 NAJ SHARIF DIRECTOR 1.00 X 0 0 0 JAI G PAREKH DIRECTOR 1.00 X 0 0 0 PATRICIA HILL DIRECTOR 1.00 X 0 0 0 JOE ROSEN DIRECTOR 1.00 X 0 0 0 LOUIS PASQUALE DIRECTOR 1.00 X 0 0 0 SHELDON M SIEGEL DIRECTOR 1.00 X 0 0 0 BARBARA CALABA DIRECTOR 1.00 X 0 0 0 CAROLE DARDEN-LLOYD DIRECTOR 1.00 X 0 0 0 ALON HARRIS DIRECTOR 1.00 X 0 0 0 ANNETTE GROLLMAN DIRECTOR 1.00 X 0 0 0 BARBARA HEARST DIRECTOR 1.00 X 0 0 0 JOSEPH F PANARELLI DIRECTOR 1.00 X 0 0 0 JOHN BERDAHL DIRECTOR 1.00 X 0 0 0 ELENA STURMAN PRESIDENT & CEO 40.00 X 350733 0 10522 NILDA RICHARDS CONTROLLER & TREASURER 40.00 X 114690 0 3453 ELENA CLY FOWKES DIRECTOR OF SPECIAL PROJECT 40.00 X 132623 0 3979 598046 0 17954 3 0 1 0 0 2676417 2676417 386991 386991 3431277 1731599 1699678 1699678 1699678 4763086 0 0 2086669 649750 649750 350000 350000 514170 359919 59642 94609 309404 261097 23008 25299 9254 7812 688 754 51289 40820 2282 8187 48629 36832 4710 7087 30875 30875 123984 123984 85963 30875 55088 42005 31814 4070 6121 94238 71377 9127 13734 32317 32317 156190 156190 2136 1618 206 312 7543 5713 731 1099 DIRECT MAIL 190484 95242 95242 COMMUNITY OUTREACH 128483 128483 POSTAGE AND SHIPPING 26007 24130 1877 OTHER 25626 5675 10821 9130 2878347 2289664 296234 292449 831853 555152 2611637 4136349 25000 385000 48048 45714 97438 95601 3973 1837 8583863 8532604 172827 205252 117121 12309626 13946604 50382 48796 315000 564750 188835 96427 554217 709973 X 7033197 7631205 4722212 5605426 11755409 13236631 12309626 13946604 1884739 -403517 0 X X 0 1 X 1 0 X 2083603 2283227 3616583 2557425 2676417 13217255 2083603 2283227 3616583 2557425 2676417 13217255 3994563 9222692 124172 107891 98435 325797 386991 1043286 60000 30000 90000 14350541 0.64270 0.63440 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8757497 379932 1434859 941932 9630356 9907875 213554 -1150556 213376 8757497 8269730 928876 1587431 878162 9907875 7068382 796746 955139 550537 8269730 5870246 483214 1221076 506154 7068382 0.46700 0.53300 0 0 97438 95601 1837 1837 OPERATING LEASE LIABILITY 96427 96427 X 4235585 -403517 -403517 4639102 123984 123984 4763086 2754363 0 2754363 123984 123984 2878347 PART V, LINE 4: THE ORGANIZATION'S ENDOWMENT FUNDS ARE INTENDED TO BE USED FOR MEDICAL RESEARCH GRANTS. PART X, LINE 2: THE FOUNDATION DOES NOT BELIEVE ITS FINANCIAL STATEMENTS INCLUDE ANY MATERIAL, UNCERTAIN TAX POSITIONS. TAX FILINGS FOR PERIODS ENDING DECEMBER 31, 2020 AND LATER ARE SUBJECT TO EXAMINATION BY APPLICABLE TAXING AUTHORITIES. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES GRANTS GRANTS 230000 EAST ASIA AND THE PACIFIC GRANT GRANTS 120000 0 0 0 0 0 0 350000 0 350000 CANADA MEDICAL RESEARCH 100000 WIRE 0 SINGAPORE MEDICAL RESEARCH 60000 WIRE 0 SINGAPORE MEDICAL RESEARCH 60000 WIRE 0 CANADA MEDICAL RESEARCH 70000 WIRE 0 CANADA MEDICAL RESEARCH 60000 WIRE 0 3 0 0 0 0 0 0 PART I, LINE 2: RECIPIENTS MUST SUBMIT SEMI-ANNUAL REPORTS SHOWING PROGRESS AND EXPENDITURES. X X X 1 FAIRCOM NEW YORK 12 W 27TH ST FL 13 NY NY 10001 DIRECT MAIL & FUNDRAISING 0 514143 61750 452393 514143 61750 452393 1 ICAHN SCHOOL OF MEDICINE 1 GUSTAVE L LEVY PL NEW YORK NY 10029 136171197 501(C)(3) 100000 0 MEDICAL RESEARCH THE REGENTS OF THE UNI CALI 1111 FRANKLIN ST OAKLAND CA 94607 956006143 501(C)(3) 189750 0 MEDICAL RESEARCH UNIVERSITY OF PITTSBURG 203 LOTHROP ST PITTSBURGH PA 15213 250965591 501(C)(3) 60000 0 MEDICAL RESEARCH WASHINGTON UNIVERSITY 660 SOUTH EUCLID AVENUE ST LOUIS MO 63110 430653611 60000 0 MEDICAL RESEARCH GEORGIA TECH RESEARCH CORPORATION 901 ATLANTIC DR NW ATLANTA GA 303320400 580603146 501(C)(3) 60000 0 MEDICAL RESEARCH JOHN HOPKINS UNIVERSITY 400 N BROADWAY BALTIMORE MD 21287 520595110 501(C)(3) 60000 0 MEDICAL RESEARCH MASSACHUSETTS EYE AND EAR INFIRMARY 243 CHARLES ST BOSTON MA 02114 042103591 501(C)(3) 60000 0 MEDICAL RESEARCH RESEARCH FOUNDFOR THE STATE UNIVOF NY 750 E ADAMS STREET SYRACUSE NY 13210 141368361 501(C)(3) 60000 0 MEDICAL RESEARCH 8 PART I, LINE 2: RECIPIENTS MUST SUBMIT SEMI-ANNUAL REPORTS SHOWING PROGRESS AND EXPENDITURES. X X X 0 0 0 0 0 0 0 0 0 ELENA STURMAN PRESIDENT & CEO 350733 0 0 0 0 0 10522 0 0 0 361255 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE CHIEF EXECUTIVE OFFICER AND THE ASSISTANT TREASURER REVIEW THE FORM 990 IN DETAIL AND THEN MAKE IT AVAILABLE TO THE GOVERNING BOARD PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A BOARD APPROVED CONFLICTS OF INTEREST POLICY. EACH BOARD MEMBER MUST FILL OUT AN ANNUAL DECLARATION STATING THEY HAD NO CONFLICTS OR IDENTIFYING THE NATURE OF THEIR INTERESTED PARTY TRANSACTIONS. FORM 990, PART VI, SECTION B, LINE 15A EACH YEAR, THE EXECUTIVE COMMITTEE REVIEWS COMPARABLE SALARIES BASED ON A RECOGNIZED STUDY AND REVIEWS THE PERFORMANCE OF THE EXECUTIVE DIRECTOR TO DETERMINE IF THE EXISTING SALARY FALLS WITHIN THESE RANGES. AFTER A DELIBERATION OF THIS MATTER, A NEW PROPOSED SALARY AND BENEFIT PACKAGE IS VOTED ON. THE MINUTES OF THE BOARD OF DIRECTORS REFLECT THE NATURE OF THIS PROCESS EACH YEAR, THE EXECUTIVE COMMITTEE REVIEWS COMPARABLE SALARIES BASED ON A RECOGNIZED STUDY AND REVIEWS THE PERFORMANCE OF THE PRESIDENT/CEO TO DETERMINE IF THE EXISTING SALARY FALLS WITHIN THESE RANGES. AFTER A DELIBERATION OF THIS MATTER, A NEW PROPOSED SALARY AND BENEFIT PACKAGE IS VOTED ON. THE MINUTES OF THE BOARD OF DIRECTORS REFLECT THE NATURE OF THIS PROCESS FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS PUBLIC DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO PUBLIC. FORM 990 PART XII LINE 2C THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.